The nucleoside antagonist cordycepin causes DNA double strand breaks in breast cancer cells

Investigational New Drugs

Volumn 30, Issue 5, 2012, Pages 1917-1925

  Lee, Hong Jue ^a,c   Burger, Petra ^a   Vogel, Marianne ^a   Friese, Klaus ^a,b   Brüning, Ansgar ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Center for Breast Health and Gynecologic Endocrinology   (South Korea)

Author keywords

H2AX; 3 deoxyadenosine; Breast cancer; Cordycepin; DNA damage

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CORDYCEPIN; DNA; HISTONE; HISTONE GAMMA H2AX; RNA; UNCLASSIFIED DRUG;

ADVANCED CANCER; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL DEATH; CELL STRAIN MCF 7; CELL STRAIN MCF10A; CELL STRAIN MDA MB 231; CELL STRAIN MDA MB 435; CELL STRAIN MDA MB 453; CELL STRAIN T47D; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; GENOTOXICITY; GROWTH INHIBITION; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; INCUBATION TIME; METABOLIC INHIBITION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RNA SYNTHESIS; TUMOR DIFFERENTIATION;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYADENOSINES; DNA BREAKS, DOUBLE-STRANDED; DNA-BINDING PROTEINS; FEMALE; HISTONES; HUMANS; MCF-7 CELLS; NUCLEIC ACID SYNTHESIS INHIBITORS; NUCLEOSIDES; PHOSPHORYLATION; POLY ADENOSINE DIPHOSPHATE RIBOSE; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; RIBONUCLEOSIDES; TUMOR SUPPRESSOR PROTEINS;

EID: 84867887068     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9859-x     Document Type: Review

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Levi F, Bosetti C, Lucchini F, Negri E, La Vecchia C (2005) Monitoring the decrease in breast cancer mortality in Europe. Eur J Cancer Prev 14:497-502
3. Dawood S (2010) Triple-negative breast cancer: epidemiology and management options. Drugs 70:2247-58
4. Paterson RR (2008) Cordyceps: a traditional Chinese medicine and another fungal therapeutic biofactory? Phytochemistry 69:1469-1495
5. Kodama EN, McCaffrey RP, Yusa K, Mitsuya H (2000) Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells. Biochem Pharmacol 59:273-281
6. Yoshikawa N, Nakamura K, Yamaguchi Y, Kagota S, Shinozuka K, Kunitomo M (2004) Antitumour activity of cordycepin in mice. Clin Exp Pharmacol Physiol 31:S51-3
7. Nakamura K, Konoha K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K, Kunitomo M (2005) Effect of cordycepin (3'-deoxyadenosine) on hematogenic lung metastatic model mice. In Vivo 19:137-141
8. Chen LS, Stellrecht CM, Gandhi V (2008) RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells. Br J Haematol 140:682-391
9. Lee SJ, Moon GS, Jung KH, Kim WJ, Moon SK (2010) c-Jun N-terminal kinase 1 is required for cordycepin-mediated induction of G2/M cell-cycle arrest via p21WAF1 expression in human colon cancer cells. Food Chem Toxicol 48:2772-2783
10. Noh EM, Youn HJ, Jung SH, Han JH, Jeong YJ, Chung EY, Jung JY, Kim BS, Lee SH, Lee YR, Kim JS (2010) Cordycepin inhibits TPA-induced matrix metalloproteinase-9 expression by suppressing the MAPK/AP-1 pathway in MCF-7 human breast cancer cells. Int J Mol Med 25:255-260
11. Jeong JW, Jin CY, Park C, Hong SH, Kim GY, Jeong YK, Lee JD, Yoo YH, Choi YH (2011) Induction of apoptosis by cordycepin via reactive oxygen species generation in human leukemia cells. Toxicol In Vitro 25:817-824
12. Thomadaki H, Tsiapalis CM, Scorilas A (2005) Polyadenylate polymerase modulations in human epithelioid cervix and breast cancer cell lines, treated with etoposide or cordycepin, follow cell cycle rather than apoptosis induction. Biol Chem 386(5):471-80
13. Kim H, Naura AS, Errami Y, Ju J, Boulares AH (2011) Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP. Mol Med. doi: 10.2119/molmed.2011. 00032
14. Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461:1071-1078
15. Miwa M, Masutani M (2007) PolyADP-ribosylation and cancer. Cancer Sci 98:1528-1535
16. Weil MK, Chen AP (2011) PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer 35:7-50
17. Plesca D, Mazumder S, Almasan A (2008) DNA damage response and apoptosis. Methods Enzymol 446:107-122
18. North TW, Cohen SS (1978) Erythro-9-(2-hydroxy-3-nonyl)adenine as a specific inhibitor of herpes simplex virus replication in the presence and absence of adenosine analogues. Proc Natl Acad Sci USA 75:4684-4688
19. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1-22
20. Amar S, Roy V, Perez EA (2009) Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Res Treat 114:413-422
21. Swain SM (2011) Chemotherapy: updates and new perspectives. Oncologist 16(Suppl 1):30-39
22. Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125:627-636
23. Cimprich KA, Cortez D (2008) ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 9:616-627
24. Riches LC, Lynch AM, Gooderham NJ (2008) Early events in the mammalian response to DNA double-strand breaks. Mutagenesis 23:331-339
25. López-Contreras AJ, Fernandez-Capetillo O (2010) The ATR barrier to replication-born DNA damage. DNA Repair (Amst) 9:1249-1255
26. Roos WP, Kaina B (2006) DNA damage-induced cell death by apoptosis. Trends Mol Med 12:440-450
27. Carden CP, Yap TA, Kaye SB (2010) PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Current Opinion in Oncology 22:473-480
28. Turner N, Tutt A, Ashworth A (2011) Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4:814-819
29. Rastelli F, Biancanelli S, Falzetta A, Martignetti A, Casi C, Bascioni R, Giustini L, Crispino S (2010) Triple-negative breast cancer: current state of the art. Tumori 96(6):875-88
30. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22(suppl 11):3-10
31. Klenow H (1963) Formation of the mono-, di-, and triphosphate of cordycepin in Ehrlich ascites-tumor cells in vitro. Biochim Biophys Acta 76:347-353
32. Cory JG, Suhadolnik RJ, Resnick B, Rich MA (1965) Incorporation of cordycepin (3'-deoxyadenosine) into ribonucleic acid and deoxyribonucleic acid of human tumor cells. Biochim Biophys Acta 103:646-653
33. Wong YY, Moon A, Duffin R, Barthet-Barateig A, Meijer HA, Clemens MJ, de Moor CH (2010) Cordycepin inhibits protein synthesis and cell adhesion through effects on signal transduction. J Biol Chem 285:2610-2621
34. Choi S, Lim MH, Kim KM, Jeon BH, Song WO, Kim TW (2011) Cordycepin-induced apoptosis and autophagy in breast cancer cells are independent of the estrogen receptor. Toxicol Appl Pharmacol 257:165-173